作者: Koblitz, Maria Gabriela Bello ; de Oliveira, Thaís Alves ; Tonin, Angelica Priscila Parussolo ; Scherf, Katharina Anne ; Cardoso, Flávio de Souza Neves ; Ramos, Gabriela Soares Macello ; Braga, Ítalo de Oliveira ; Dias, Juliana Furtado ; da Silva, Roberta Nogueira Pereira ; Tissen, Eleonora ; Meurer, Eduardo Cesar ; Leal, Débora

Craft beer production has expanded notably in recent years, attracting increasing scientific interest due to its distinct brewing practices and nutritional potential. Unlike industrial beers, craft beers are often produced in smaller volumes without additives, filtration, or pasteurization, and their formulations frequently include diverse raw materials that can influence the nutritional profile. Particular attention has been given to bioactive peptides (BPs), short amino acid chains released from cereal and yeast proteins, which may exert antioxidant, antihypertensive, antidiabetic, and anti-inflammatory effects. However, studies specifically characterizing the peptide composition of beers remain scarce. This study aimed to characterize and compare the peptide profiles of three representative craft beer styles - Pilsner, IPA, and Witbier - by applying ultrafiltration and LC-MS/MS. The results revealed that peptide composition was highly dependent on beer style, and Witbier exhibited the greatest diversity and abundance of peptides, likely associated with the different cereals in its formulation. Barley was the main protein source, followed by wheat and yeast and both shared and unique peptides were identified across the styles. In silico prediction suggested multiple potential biological activities, highlighting antioxidant activity and peptidase inhibition (ACE, DPP-IV, DPP-III, and neprilysin inhibitors). Notably, Witbier presented the highest number of potentially bioactive peptides, followed by IPA and Pilsner. These findings provided novel insights into the functional properties of craft beers, suggesting that the recipe may play a more significant role in shaping peptide profiles than fermentation type or yeast strain. These results significantly expanded current knowledge on bioactive components in beer.

2025-12-15·Cardiovascular journal of Africa

Improving cardiac function of angiotensin receptor/ neprilysin inhibitor in patients with acute myocardial infarction: a systematic review and meta-analysis

Article

作者: Niu, Qiuli ; Wang, Changyuan ; Xing, Xiurong

AIM:

As the impact of angiotensin receptor/neprilysin inhibitor (ARNI) on cardiac function in acute myocardial infarction (AMI) patients is unclear in clinical therapy, we conducted this research to investigate the actual effects of improving cardiac function with ARNI in AMI patients.

METHODS:

Publications were checked up to June 2022. Standardised mean differences (SMD) and 95% confidence intervals (CI) were utilised for assessing the size of the effect of continuous variables. To assess the magnitude of the effect of dichotomous variables, a relative risk (RR) with 95% CI was used.

RESULTS:

ARNI could improve left ventricular ejection fraction (SMD = 0.40; 95% CI: 0.23 - 0.58), while lowering left ventricular end-diastolic volume (SMD = -0.43, 95% CI: -0.78 to -0.08), left ventricular end-systolic volume (SMD = -0.39, 95% CI: -0.66 to -0.11) and left ventricular enddiastolic diameter (SMD = -0.49; 95% CI: -0.65 to -0.33). Besides, it could decrease the rates of major adverse cardiac events (RR = 0.55; 95% CI: 0.43 - 0.69) and heart failure (RR = 0.42; 95% CI: 0.31 - 0.58).

CONCLUSION:

ARNI could greatly improve cardiac function in AMI patients.

2025-12-01·AMERICAN JOURNAL OF CARDIOLOGY

The Role of Angiotensin Receptor/Neprilysin Inhibitor in Moderate Ischemic Mitral Regurgitation After Isolated Coronary Artery Bypass Grafting (ARNI-MIMIC): Study Protocol for a Randomized Controlled Trial

Article

作者: Huang, Shengkang ; Zhao, Dong ; Chen, Lianxin ; He, Liaoming ; Song, Yangwu ; Tiemuerniyazi, Xieraili ; Hu, Zhan ; Yang, Ziang ; Yuan, Xin ; Feng, Wei ; Nan, Yifeng ; Zhao, Wei

Debates have been existed regarding the treatment of moderate ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG). While it might have priority on reducing the risk of recurrent IMR, studies showed that concomitant mitral valve repair increases the risk of adverse outcomes, such as neurological events, as well as the in-hospital costs. In recent studies, angiotensin receptor/neprilysin inhibitor (ARNI) was discovered to have potential benefit in reducing the severity of IMR. The ARNI-MIMIC is a randomized controlled clinical trial aiming to reduce the risk of recurrent IMR in isolated CABG patients. A total of 220 eligible patients with moderate IMR will be allocated into control (non-ARNI) and intervention (ARNI) groups in a 1:1 pattern after isolated CABG. Patients in the intervention group will be administered with continuous sacubitril/valsartan for 6 months postoperatively, while patients in the control group will receive guideline recommended therapy only. All of the patients will be invited to complete 6-month follow-up. The primary endpoint is the change in the effective regurgitant orifice area (EROA) of the mitral valve, which is obtained by echocardiography and calculated by subtracting the follow-up EROA from the preoperative EROA. This trial aims to investigate the potential role of ARNI as compared to the control in moderate IMR patients undergoing isolated CABG. If ARNI is proven to reduce the risk of moderate IMR recurrence, patients will benefit from both improved life quality and decreased medical costs. The This study was approved by the Institutional Review Board of Fuwai Hospital on October 18th 2024, with an approval number of 2024-2446. The results of this trail will be disseminated through international academic conferences and publication in medical journals regardless of the study outcomes. ClinicalTrials.gov ID NCT06917664.

100 项与 Neprilysin inhibitors(Birla Institute of Technology & Science) 相关的药物交易

登录后查看更多信息